SYHX2008 injection

DRUG2 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

AcromegalyGastrointestinal Neuroendocrine Pancreatic Tumor

Phase 1

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

CompletedNCT05761431

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Acromegaly

Start: 2023-03-02End: 2023-06-28Updated: 2023-10-10

Phase 2

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

RecruitingNCT06505395

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Gastrointestinal Neuroendocrine Pancreatic Tumor

Start: 2024-07-30End: 2028-08-01Target: 90Updated: 2024-08-26